Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mycovia Pharmaceuticals

https://www.mycovia.com/

Latest From Mycovia Pharmaceuticals

Six Key Infectious Disease New Drug Launches To Look Out For In 2022

In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.

Companies Approvals

Coccidioidomycosis Outlook Highlights The Limits Of Regulatory Incentives

The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.

Rare Diseases Review Pathway

Signs Of Life In The Bacterial Vaginosis, Vulvovaginal Candidiasis Pipeline

Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.

Naturex Offers Sustainable Weight Loss With Svetol

“This is not a miracle drug or a quick fix, but can be effective over time for individuals who are committed to losing weight,” said Naturex R&D chief Antoine Bily. Svetol is a natural plant extract of decaffeinated green coffee.

Consumer France
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register